Medicine and Health Sciences Commons^™

Analysis Of Antibody Drug Conjugate On Cellular Senescent Human Glioblastoma, Ariel P. Walker, Renee Hirte, Cecile Riviere-Cazaux, Authur Warrington, Terry Burns

Medical Student Research Symposium

Background: Glioblastoma Multiforme (GBM) is an aggressive and malignant brain tumor known for its rapid progression and unfavorable prognosis. The standard treatment options primarily involve radiation and temozolomide, however recurrence is inevitable.

B7H3/CD276, an immunomodulatory transmembrane glycoprotein, demonstrates tumor-specific expression, with limited presence in normal healthy tissue, making it a promising and attractive treatment target in GBM. AbbV155 is an antibody drug conjugate that inhibits BCL-XL and specifically targets B7H3 (CD276) on GBM cells with the goal of selectively eliminating viable tumor cells.

Objectives: First, we sought to confirm the presence of B7H3/CD276 in our selected cell line via …